



# PATENT

*Ifw*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**STROBEL, et al.**

Examiner: Powers, F.

Art Unit: 1626

Application No.: **10/632,083**

Filed: **July 31, 2003**

Title: **ACYLATED, HETEROARYL-CONDENSED  
CYCLOALKENYLAMINES AND THEIR USE  
AS PHARMACEUTICALS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 15, 2005

Date of Deposit

Paul Irvine

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



---

Joseph D. Rossi, Reg. No. 47,038  
Attorney for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3410  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2002/0057 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/632,083
				Filing Date	07-31-2003
				First Named Inventor	STROBEL
				Group Art Unit	1626
				Examiner Name	Powers, F.
Sheet	2	of	4	Attorney Docket Number	DEAV2002/0057 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BIANCHI, et al., Regioselectivity in the Reactions of Benzonitrile N-Phenyl-Imide and Some Benzonitrile N-Oxides with a,B-Unsaturated Ketones., J. Chem. Res, Synop. (1981) 6-7	
		BINDER, et al., A Facile Route to Functionalized Cyclopenta [b] thiophenones Based on the Structure of the Selective COX-2 Inhibitor Flosulide, Monatsh. Chem 129, (1998), 887-896	
		CAPRATHE, et al., Dopamine Autoreceptor Agonists as Potential Antipsychotics. 3. 1 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo [4,5-f] quinolin-2-amine, J. Med. Chem. 34, (1991), 2736-2746	
		DAMMERTZ, et al., Synthese Von 6,7,8,9-Tetrahydro-5H-cyclohepta[b] pyridin-5-on, Arch. Pharm. 310 (1977), 172-176	
		ENDRES, et al., Stroke Protection By 3-Hydroxy-3-Methylglutaryl (HMG) - CoA Reductase Inhibitors Medicated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 95 (1998) 8880-8885	
		HICKS, et al., The Synthesis And Photochemical Behaviour Of Some Annelated Tropones, J. Chem. Soc. Perkin Trans. 1, (1984) 2297-2304	
		HOFFMAN, et al., Synthesis Of 3-Nitro-5-Acylpyridines By Condensation Of Sodium Nitromalonaldehyde/Tosyl Chloride With 2-Amino-1-Acyl Olefins. Evidence For the Intermediacy of 3-Chloro-2-Nitroacrolein, J. Org. Chem. 49 (1984), 193-195	
		HUANG, et al., The Improved Preparation Of 7,8-Dihydro-Quinoline-5(6H)-One and 6,7-Dihydro-5H-1-Pyridin-5-One, Synth. Commun. 28 (1998), 1197-1200	
		JONES, et al., Synthesis Of 4H-Cyclohepta [b] thiophen-4-ones, 4H-Cyclohepta [b] furan-4-one, and 9H-Cyclohepta[b] pyridin-9-one, J. Chem. Soc., Perkin Trans., 1, (1973), 968-972	
		KOEHLER, et al., Potential Anticancer Agents IX. Tetrahydroquinazoline Analogs Of Tetrahydrofolic Acid. I, J. Am. Chem. Soc. 80 (1958) 5779-5785	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/632,083
				Filing Date	07-31-2003
				First Named Inventor	STROBEL
				Group Art Unit	1626
				Examiner Name	Powers, F.
Sheet	3	of	4	Attorney Docket Number	DEAV2002/0057 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LI, et al., Activation Of Protein Kinase Ca and/or e Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol. 53 (1998) 630-637	
		MACDOWELL, et al., The Use Of 2,5-Dichlorothiophene In The Synthesis Of 3,4-Disubstituted Thiophenes, J. Org. Chem. Soc. 32 (1967) 1226-1229	
		MOROI, et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, J. Clin. Invest., 101 (1998) 1225-1232	
		MURARO, et al., Heterocycles sulfures condenses. - Synthese et dechloration de dichloro-1,3 thieno (c) cyclenones,, Bull. Soc. Chim. Fr., Pt. 2, (1973) 335-342	
		MURARO, et al., Recherches dans le domaine des thieno (c) cyclenones. , C.R. Acad. Sci., Ser. C, 273 (1971) 1362-1367	
		NAKAYAMA, et al., T- 786 - C Mutation in the 5' -Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Circulation 99 (1999) 2864-2870	
		NAYYAR, et al., New Approach for the General Synthesis of Oxotetrahydroindoles via Intramolecular Cycloadditions of Azomethine Ylides with Tethered Alkynes, J. Org. Chem. 62 (1997) 982-991	
		RAVINA, et al., Conformationally Constrained Butyrophenones with Mixed Dopaminergic (D2) and Serotonergic (5-HT2A, 5-HT2C) Affinities: Synthesis, Pharmacology, 3D-QSAR, and Molecular Modeling of (Aminoalkyl) benzo- and - thienocycloalkanones as Putative Atypical Antipsychotics, J. Med. Chem. 42 (1999) 2774-2797	
		REIMANN, et al., Regioselektive Synthese von 4-Methyl-1-pyridin-5-on, Pharmazie 50 (1995) 589-592	
		RUANGSIYANAND, et al., Enamine Cyclischer 1,3-Diketone als Ausgangsstoffe fur Pyridinringsynthesen, Chem. Ber. 103 (1970) 2403-2410	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/632,083
				Filing Date	07-31-2003
				First Named Inventor	STROBEL
				Group Art Unit	1626
				Examiner Name	Powers, F.
Sheet	4	of	4	Attorney Docket Number	DEAV2002/0057 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SCHENONE, et al. , Reaction of 2-Dimethylaminomethylene-1,3-diones with Dinucleophiles. I. Synthesis of 1,5-Disubstituted 4-Acylpyrazoles, J. Heterocyclic Chem., 19 (1982) 1355-1361	
		SCHROEDER, et al., Nichtsteroidale Entzündungshemmer. 3. Substituierte Aza-Tetralin - und Aza-indancarbonsauren Mit Antiphlogistischer Wirkung, J. Med. Chem. - Chim. Ther. 14 (1979) 309-315	
		SESSA, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research 74 (1994) 349-353	
		SHIGEKI, et al., 7-Oxocyclopenta[d]Pyrimidine Derivative, esp@cenet database - 12 -Document Bibliography and Abstract	
		TAKESHI, et al., Benzoic Acid Derivative Or Its Salt, esp@cenet database -12 - Document Bibliography and Abstract	
		VARENNE, et al. , Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 11 (2000) 1329-1339	
		WESTERWELLE, et al., B-Aminoketone als Schlüsselverbindungen zur Synthese von Pyridinen: Ein Neuartiger, Leistungsfähiger Zugang zu Kondensierten Bi- und Terpyridinen, Chem. Ber. 124 (1991) 571-576	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.